MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has made a significant leap in the field of neurodegenerative disease treatment with the issuance of a U.S. patent for its lead drug candidate, buntanetap. The patent, U.S. Patent No. 12,042,482, focuses on methods for treating acute traumatic brain injuries (TBI) and preventing nerve cell death.
In 2016, Annovis Bio filed a comprehensive patent covering the treatment of various nerve insults, including TBI, stroke, and nerve and spinal cord injuries. While these claims were granted globally, the U.S. Patent and Trademark Office (USPTO) required the claims to be separated into individual patents for each condition. The newly issued patent specifically addresses TBI, a prevalent issue in the United States.
“We are thrilled to achieve this significant milestone for buntanetap,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. “Nerve cell death is a common underlying factor in many brain conditions, beyond just Alzheimer’s and Parkinson’s. Our preclinical studies in TBI and stroke animal models have demonstrated buntanetap’s efficacy in preventing cell death and loss of function, and it is our duty to explore its potential benefits for victims of brain trauma, a prevalent issue in the U.S.”
This patent not only solidifies Annovis Bio’s intellectual property portfolio but also enhances its strategic position in the neurodegenerative treatment market. The company’s portfolio includes a range of patents and applications covering the use of buntanetap for both acute and chronic neurodegenerative diseases, as well as mental illnesses.
The business implications of this patent are profound. Traumatic brain injuries are a significant public health issue, affecting millions every year. The ability to treat TBI effectively could lead to reduced healthcare costs, improved patient outcomes, and a substantial market opportunity for Annovis Bio. The company’s innovative approach aims to restore brain function and improve the quality of life for patients suffering from various neurodegenerative disorders.
As the healthcare community continues to seek effective treatments for neurodegenerative diseases, Annovis Bio’s developments with buntanetap could mark a pivotal moment in improving patient care and outcomes.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.